Dr. Abbey Presents ARCHER II Clinical Trial Data at The Retina Society Annual Scientific Meeting
Texas Retina’s Ashkan Abbey, MD, presented baseline characteristics of participants in the Phase 3 ARCHER II clinical trial for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) at the 59th
read more
A New Way to Explore Career Opportunities at Texas Retina
Texas Retina has launched a new Careers page to make it easier to learn about career opportunities and current openings within our organization. For more than six decades, Texas Retina has brought
read more
Frequently Asked Questions About Eye Injections
For many retinal diseases like age-related macular degeneration, diabetic retinopathy, retinal vein occlusion and uveitis, an eye injection (also called an intravitreal injection) is the only way we can deliver potentially sight-saving medication where it is needed
read more
Dr. Abbey Receives 2026 Achievement Award from the American Academy of Ophthalmology
Texas Retina’s Ashkan M. Abbey, MD, has earned the 2026 Achievement Award from the American Academy of Ophthalmology (AAO) in recognition of his contributions to the Academy, its scientific and educational programs,
read more
Dr. Abbey Discusses the Use of VABYSMO® for Polypoidal Choroidal Vasculopathy
In the current issue of Ocular Surgery News on Healio, Texas Retina’s Ashkan M. Abbey, MD, shares his perspective on the recently reported two-year results from the Phase 3b/4 SALWEEN study evaluating
read more
Dr. Choi Develops New Surgical Technique for Macular Holes That Fail to Close After Initial Surgery
Texas Retina’s Rene Y. Choi, MD, PhD, recently published a case report in the medical journal Retinal Cases & Brief Reports describing a surgical technique he developed to treat macular holes that
read more



